// App-Quantinova.ai

: Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Michael J. Morris

Principal Investigators

  • Mark David Linch

  • Simon J. Crabb

  • Tomasz M. Beer

  • Elisabeth I. Heath

  • Michael S. Gordon

  • Johann S. De Bono

  • Hristina I Pashova

  • Iulia Cristina Tudor

  • Andrew E Greenstein

  • Grace Mann

  • Glenn Liu

Medical Centers

  • Corcept Therapeutics, Menlo Park, CA

  • Knight Cancer Institute, Portland, OR

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Barbara Ann Karmanos Cancer Institute,Wayne State University School of Medicine, Detroit, MI

  • Univ. of Wisconsin-Madison Carbone Cancer Center, Madison, WI.

  • HonorHealth Research and Innovation Institute, Scottsdale, AZ

  • The Institute of Cancer Research, Sutton, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacodynamics

  • Double Blind/Blinded

  • Open Label

Phase

  • I

Study Id's

  • NCT03437941

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved